American Heart Association Get With the Guidelines to be included in Cardiology & Heart Surgery specialty rankings by U.S. News & World Report #BestHospitals

Opportunity for national recognition for improving CV/stroke care and outcomes

Clyde Yancy, MD, MSc Robert Harrington Adrian “WE NEED RCTS!” Hernandez Dr. Deepak L. Bhatt Don Lloyd-Jones Jonathan Piccini, MD, MHS

🚨Stunning!🚨

REVERSAL in the decline of heart failure ☠️ in the US 1999-2021

1999-2005 ⬇️ ☠️
2005-2012 ⬇️ ☠️
2012-2019 ⬆️ ☠️
2019-2021 ⬆️⬆️☠️

Age-adjusted HF related ☠️ rates higher in 2021 vs 1999!

WT😱🆘

jamanetwork.com/journals/jamac…

JAMA Cardiology Marat Fudim, MD MHS

Impressive data on HFrEF: Although 82% of patients are eligible for quadruple therapy at discharge, only 15% actually receive it. This underutilization could significantly impact patient outcomes.

Gregg Fonarow MD JACC Journals American College of Cardiology Circulation European Society of Cardiology News

jacc.org/doi/10.1016/j.…

⚠️Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical 💊
for Newly Diagnosed #HF

👥 33036 🇺🇸newly diagnosed with HFrEF
👉82% were eligible for4️⃣💊,
👉93% were eligible for 3️⃣💊

⏰ 2021- 2023, of 👥 eligible for 4️⃣💊
▶️15.3% were prescribed 4️⃣💊
▶️41.5%

We have to shift the acute care mindset beyond 'diurese & discharge' with ADHF. #GDMT saves lives and we must strive to get patients on quadruple therapy while hospitalized

Bailey Ann Estes Viet Le DMSc PA-C FACC FAHA HF-Cert Andrea Price, RCIS, CPHQ, AACC Derek Pineda Gregg Fonarow MD Steve Greene

Check out our review on 'SGLT2i and GU infections' in JACC Journals

🔗: shorturl.at/gsGL7

Here we discuss
- SGLT2i mechanisms/benefits
- Trial/real-world evidence of SGLT2i/GU ifx
- Risk factors
- Practice considerations

🧵 to follow (1/5)

ICYMI: In our #ACC24 episode of #DontMissABeat , Javed Butler joined @SJGreene_MD and @MVaduganathan to discuss EMPACT-MI.

#Cardiology #HeartFailure

hcplive.com/view/don-t-mis…

Proud of our chief fellow Duke Cardiology Fellows Joe Lerman, MD and future Duke Heart Failure fellow for his excellent presentation of impact of UNOS allocation on PGD ❤️💙!!

The ISHLT Duke Clinical Research Institute Richa Agarwal Adam DeVore, MD, MHS Robert Mentz, MD Manesh Patel

Jacob Niall Schroder Speaking The ISHLT on Real World Clinical Outcomes of DCD Heart Transplantation from the OCS Heart Perfusion Registry: Benchmarking to Other Preservation Methods Duke Heart Duke Surgery Duke Heart Failure Adam DeVore, MD, MHS Richa Agarwal

Hospital costs for those with #HFrEF tend to be high – yet the factors that contribute to these costs vary. DCRI Fellow Mark Kittipibul MD sat down with HCPLive at #ACC24 to discuss the GWTG-HF registry, and how to reduce HF-related costs: hcplive.com/view/understan…

Cause-Specific Healthcare Costs Following Hospitalization for Heart Failure and Cost Offset with SGLT2i

👥146,003
📌34.7% EF≤40%
📌65.3% EF>40%
💰Mean total cost through 1-year was $40,557
👥EF>40% had higher costs due to non-HF and non-CV🏥
🧮5 SGLT2i clinical trials

🔴 Prioritizing prevention of de novo and worsening chronic heart failure #openaccess #editorial

onlinelibrary.wiley.com/doi/10.1002/ej…
#meded #medtwitter #medical #cardiology #CardioTwitter #CardioEd
Steve Greene Ankeet S. Bhatt, MD, MBA Gregg Fonarow MD

In the ARISE-HF RCT of 691 pts w #diabetic #cardiomyopathy , selective aldose reductase inhibitor #AT001 did not change peak VO2 at 15 months

Tx interaction w baseline SGLT2i, GLP1RA use

James Januzzi Jr MD & I discuss the rationale, methods, results #ACC24

sciencedirect.com/science/articl…

“In this post-hoc on-treatment analysis of TRANSFORM-HF — inclusive of all randomized patients, unless they were confirmed to be non-adherent — there was no significant difference in outcomes between torsemide and furosemide,” said DCRI Fellow Mark Kittipibul MD at #ACC24 .

Not much has changed in AHF 🏨 weight change in the >2 decades since first reported in ADHERE

Contemporary Decongestion Strategies in Patients Hospitalized for Heart Failure: A National Community-Based Cohort Study | JACC: Heart Failure jacc.org/doi/10.1016/j.…

Alex Sandhu

Hospital-at-home has the potential to increase “home-time” & lower costs. In this analysis, the authors queried EMRs to estimate & characterize hospitalized HF pts eligible for HaH - of great importance to 🏥 & national policymakers! #ACC #JCF

🔗 bit.ly/3TL7pEl

In patients hospitalized with AHF, moderate-severe MR & TR may impact decongestion and outcomes ➡️ implementation of evidence-based interventions in this high risk population is 🔑

Grateful for mentorship from Steve Greene and fun with the Duke IM Residency #Dukefam at #ACC24 🫀

#ACC24 Jimmy Zheng presenting on diuretic strategies in national sample of ADHF. Not much has changed since ADHERE registry Andrew P. Ambrosy, MD Stanford Department of Medicine

#ACC24 #LBCT AJ Blood, MD, MS presenting the results of DRIVE study that was run by our Accelerator for Clinical Transformation research team. A remote pharmacist and navigator driven program increases SGLT2i and GLP1-RA prescriptions in patients with T2DM. Sim pub Circulation

Our Penn Cardiology real-world experience with #mavacamten in patients with symptomatic #cvHCM — largest cohort with longest follow-up to date published — out now as simultaneous publication in JACC Journals #JACCHF !

Anjali Owens